Immunovant ditches lupus for multi-hyphenate inflammatory drug after mid-stage miss

Phase 2negativeimeroprubartNegative

AI Analysis

Summary

Immunovant's imeroprubart failed to meet efficacy requirements in a Phase 2b lupus trial and will be discontinued for this indication. The company is redirecting the drug toward potential use in neurology, endocrinology, and rheumatology indications.

Clinical Trial Data

Phase

Primary Endpoint

Not Met

Outcome Details

Failed to demonstrate sufficient efficacy in lupus during Phase 2b trial

Importance:6/10

Sentiment:

-0.70

Phase 2b failurelupusclinical trial missprogram discontinuationindication shift

Related Companies

$IMVT

Read the original article

Published by BioSpace on September 23, 2026 3:15 PM

Read Original